Cargando…

Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C

In clinical trials, sofosbuvir showed high antiviral activity in patients infected with hepatitis C virus (HCV) across all genotypes. We aimed to determine the cost-effectiveness of sofosbuvir-based treatment compared to current standard treatment in mono-infected patients with chronic hepatitis C (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pfeil, Alena M., Reich, Oliver, Guerra, Ines M., Cure, Sandrine, Negro, Francesco, Müllhaupt, Beat, Lavanchy, Daniel, Schwenkglenks, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431849/ https://www.ncbi.nlm.nih.gov/pubmed/25974722 http://dx.doi.org/10.1371/journal.pone.0126984

Ejemplares similares

Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
por: Müllhaupt, Beat, et al.
Publicado: (2018)

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2017)

Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland
por: Müllhaupt, Beat, et al.
Publicado: (2015)

Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening Recommendations
por: Bertisch, Barbara, et al.
Publicado: (2016)

Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study
por: Brezzi, Matteo, et al.
Publicado: (2019)

All-Cause Mortality and Causes of Death in the Swiss Hepatitis C Cohort Study (SCCS)
por: Roelens, Maroussia, et al.
Publicado: (2020)

Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C
por: Leleu, H, et al.
Publicado: (2015)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
por: McEwan, Phil, et al.
Publicado: (2017)

Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US
por: Zhang, Sai, et al.
Publicado: (2015)

Prevalence of hepatitis C in a Swiss sample of men who have sex with men: whom to screen for HCV infection?
por: Schmidt, Axel J, et al.
Publicado: (2014)

Temporal trends and regional disparities in cancer screening utilization: an observational Swiss claims-based study
por: Bähler, Caroline, et al.
Publicado: (2021)

Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland
por: Gutzwiller, Florian S., et al.
Publicado: (2015)

Epidemiology and costs of diabetes mellitus in Switzerland: an analysis of health care claims data, 2006 and 2011
por: Huber, Carola A, et al.
Publicado: (2014)

Estimating the prevalence of comorbid conditions and their effect on health care costs in patients with diabetes mellitus in Switzerland
por: Huber, Carola A, et al.
Publicado: (2014)

Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C
Publicado: (2019)

Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C
por: Tang, L., et al.
Publicado: (2018)

Exploring geographic variation of and influencing factors for utilization of four diabetes management measures in Swiss population using claims data
por: Wei, Wenjia, et al.
Publicado: (2020)

Trends in prevalence, mortality, health care utilization and health care costs of Swiss IBD patients: a claims data based study of the years 2010, 2012 and 2014
por: Bähler, Caroline, et al.
Publicado: (2017)

Scaling-up hepatitis C screening and treatment in Swiss outpatient psychiatric settings: A cost-effectiveness analysis
por: Girardin, François, et al.
Publicado: (2022)

Minimal Compared With Standard Monitoring During Sofosbuvir-Based Hepatitis C Treatment: A Randomized Controlled Trial
por: Davis, J S, et al.
Publicado: (2020)

Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C
por: Childs-Kean, Lindsey M, et al.
Publicado: (2019)

Increased hospital treatment volume of splenic injury predicts higher rates of successful non-operative management and reduces hospital length of stay: a Swiss Trauma Registry analysis
por: Lavanchy, Joël L., et al.
Publicado: (2021)

Economic burden of symptomatic iron deficiency – a survey among Swiss women
por: Blank, Patricia R., et al.
Publicado: (2019)

Work Characteristics of Acute Care Surgeons at a Swiss Tertiary Care Hospital: A Prospective One-Month Snapshot Study
por: Di Pietro Martinelli, Claudine, et al.
Publicado: (2021)

Sofosbuvir and daclatasvir
por: Hessel, Marleen H. M., et al.
Publicado: (2016)

Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C
por: Ogawa, Eiichi, et al.
Publicado: (2020)

Sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir: novel treatment options for naïve and previously treated hepatitis C infection
por: Shin, Hyun Phil
Publicado: (2023)

HCV disease burden and population segments in Switzerland
por: Bihl, Florian, et al.
Publicado: (2021)

Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States
por: Jayasekera, Channa R., et al.
Publicado: (2017)

Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results
por: Gandjour, Afschin
Publicado: (2020)

Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection
por: Anna, Linda Zignego, et al.
Publicado: (2018)

Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient
por: Thalhammer, Julian, et al.
Publicado: (2021)

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany
por: Buggisch, Peter, et al.
Publicado: (2019)

Efficacy and safety of sofosbuvir–velpatasvir and sofosbuvir–velpatasvir–voxilaprevir for hepatitis C in Korea: a Phase 3b study
por: Heo, Jeong, et al.
Publicado: (2023)

Rates of Hepatocellular Carcinoma After Start of Treatment for Chronic Hepatitis C Remain High with Direct Acting Antivirals: Analysis from a Swiss Liver Transplant Center
por: Karbeyaz, Fatih, et al.
Publicado: (2021)

Sofosbuvir: a novel oral agent for chronic hepatitis C
por: Cholongitas, Evangelos, et al.
Publicado: (2014)

Changing the face of hepatitis C management – the design and development of sofosbuvir
por: Noell, Bennett C, et al.
Publicado: (2015)

Hepatitis C eradication with sofosbuvir leads to significant metabolic changes
por: Morales, Amilcar L, et al.
Publicado: (2016)

Comment on the paper "Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results"
por: Mühlbacher, Axel C., et al.
Publicado: (2021)

Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir/ledipasvir in genotype 4 hepatitis C virus: A prospective comparison with historical control
por: Joharji, Hala, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c880t21bfh00m5j1rn49hnb32f